Debut Plus

₹1,134.1

▼ -30.03 -2.58%

17 Jul 2026

NSE Listed

Alivus Life Sciences Ltd. (ALIVUS)

Volume: 6,27,185Avg Vol 1W: 1,79,378.8Avg Vol 1M: 1,20,367.7552W Range:₹819₹1,193.9
NSE BSE www.alivus.com
Key Ratios
Checked 6h ago
Market Cap₹14,288 Cr
Current Price₹1,134.1
Previous Close₹1,164.13
High / Low (52w)₹1,193.9 / ₹819
Volume6,27,185
Avg Vol (1W)1,79,378.8
Avg Vol (1M)1,20,367.75
Stock P/E87.99
Book Value₹271.48
Dividend Yield43%
ROE16.94%
ROA14.17%
Revenue (TTM)₹2,421 Cr
Revenue Growth—
Profit Margin22.12%
Total Debt₹0 Cr
Shares Outstanding12 Cr
Face Value₹2
EPS (TTM)₹47.56
P/B4.29
Debt / Equity0.01
50 DMA₹1,092.02
200 DMA₹979.33
Day change-2.58%
Price Chart
₹1,134.1▲ 6.11% · 1Y
₹1168₹86030.8L
2025-07-17
2026-07-16

20-day avg volume: 1.2L shares

Pros
  • Healthy return on equity of 16.9%.
  • Pays a dividend yield of 43.0%.
  • Company is almost debt-free.
Cons
  • Revenue fell 18% YoY.
  • Stock trades at a high P/E of 88.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹589 Cr₹507 Cr₹642 Cr₹650 Cr₹602 Cr₹588 Cr₹673 Cr₹689 Cr
EBITDA₹151 Cr₹128 Cr₹186 Cr₹193 Cr₹164 Cr₹175 Cr₹226 Cr₹217 Cr
Net Profit₹111 Cr₹95 Cr₹137 Cr₹142 Cr₹122 Cr₹130 Cr₹150 Cr₹163 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹887 Cr₹1,549 Cr₹1,886 Cr₹2,138 Cr₹2,190 Cr₹2,295 Cr₹2,421 Cr₹2,552 Cr
EBITDA₹229 Cr₹455 Cr₹558 Cr₹593 Cr₹629 Cr₹633 Cr₹657 Cr₹0 Cr
Net Profit₹196 Cr₹313 Cr₹352 Cr₹419 Cr₹467 Cr₹471 Cr₹486 Cr₹564 Cr
EPS24.6429.0432.6135.6338.1138.3839.52—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹1,475 Cr₹1,726 Cr₹1,997 Cr₹2,471 Cr₹2,702 Cr₹2,850 Cr₹3,411 Cr₹3,983 Cr
Total Liabilities₹1,387 Cr₹1,324 Cr₹1,244 Cr₹417 Cr₹564 Cr₹518 Cr₹594 Cr₹651 Cr
Equity₹88 Cr₹402 Cr₹753 Cr₹2,054 Cr₹2,138 Cr₹2,332 Cr₹2,817 Cr₹3,332 Cr
Total Debt———————₹57 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹497 Cr₹736 Cr₹460 Cr₹576 Cr₹554 Cr₹565 Cr
Investing₹-69 Cr₹-122 Cr₹-147 Cr₹-116 Cr₹-616 Cr₹-570 Cr
Financing₹-214 Cr₹-79 Cr₹-388 Cr₹-279 Cr₹-6 Cr₹-64 Cr
Free Cash Flow₹497 Cr₹736 Cr₹460 Cr₹576 Cr₹554 Cr₹258 Cr
Shareholding
Promoter 74.87% Institutions 12.72% Public 12.41%
About Alivus Life Sciences Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

www.alivus.com ↗
Efficiency & Working Capital
ROCE22.3%
Interest Coverage272.4
Dividend Payout—
Debtor Days148 d
Inventory Days103 d
Payable Days60 d
Cash Conversion Cycle192 d
Working Capital Days251 d
Shareholding Details

As of 2026-06-30

Promoter74.9%
FII5.5%
DII7.2%
Institutions12.7%
Public12.4%
Promoter Pledge0%
No. of Shareholders1,25,559
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters82.8%82.8%82.8%82.8%75%75%75%74.9%74.9%74.9%74.9%74.9%
FIIs4.4%4.6%5%4.8%7.9%6.7%6.6%6.4%6.8%5.1%5.3%5.5%
DIIs0.6%0.6%1.4%1.6%4.2%4.9%5.2%5.6%5.5%7.1%7.3%7.2%
Public12.1%12%10.7%10.8%13%13.4%13.2%13%12.8%12.9%12.6%12.4%
Promoter Pledge9.5%9.5%9.5%9.5%0%0%0%0%0%0%0%0%
No. of Shareholders1,98,7641,85,5311,56,1831,49,3961,43,9601,46,8401,41,9771,38,5001,35,6431,32,7481,27,9691,25,559
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Nirma LimitedShareholding of Promoter and Promoter Group74.9%9.19 Cr
Quant Mutual Fund - Quant Small Cap FundPublic Shareholding2.5%30,80,136
Government Pension Fund GlobalPublic Shareholding2.4%29,50,000
Massachusetts Institute Of TechnologyPublic Shareholding1.2%15,04,000
Karnavati Holdings Inc., UsaShareholding of Promoter and Promoter Group0%0
Searles Valley Minerals Inc., UsaShareholding of Promoter and Promoter Group0%0
Searles Valley Minerals Europe, FranceShareholding of Promoter and Promoter Group0%0
Searles Domestic Water Company Llc, UsaShareholding of Promoter and Promoter Group0%0
Trona Railway Company Llc, UsaShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Nirma Limited00%2026-06-30
Karnavati Holdings Inc., Usa00%2026-06-30
Searles Valley Minerals Inc., Usa00%2026-06-30
Searles Valley Minerals Europe, France00%2026-06-30
Searles Domestic Water Company Llc, Usa00%2026-06-30
Trona Railway Company Llc, Usa00%2026-06-30
Quant Mutual Fund - Quant Small Cap Fund00%2026-06-30
Government Pension Fund Global00%2026-06-30
Massachusetts Institute Of Technology00%2026-06-30
Nirma Limited00%2026-03-31
Karnavati Holdings Inc., Usa00%2026-03-31
Searles Valley Minerals Inc., Usa00%2026-03-31
Board of Directors
NameDesignationYear
HIREN KARSANBHAI PATELChairman & Independent Directo2025
Yasir Yusufali RawjeeManaging Director & CEO2025
Vinod NaikED / WTD / Head - Technical & Operations2025
KAUSHIKBHAI NANDUBHAI PATELIndependent Non Exe. Director2025
Manju AgarwalIndependent Non Exe. Director2025
Taruvai Laxminarayanan EaswarIndependent Non Exe. Director2025
Savan GodialwalaIndependent Non Exe. Director2025
Rudalf CorrieaCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
API₹0 Cr—
Segments — Geography
RegionRevenueShare
Within India₹1,152 Cr48.3%
Outside India₹1,235 Cr51.7%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹2402525
Corporate Actions
TypeDateValueRemark
dividend2025-09-01₹5 (250%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202500025025
202500025025
2025000000
Insider / Designated-Person Trades

8 recent disclosure(s)

Glenn Mario SaldanhaDisposal · 7,800
Glenmark Pharmaceuticals LimitedDisposal · 96,09,571
Nirma LimitedAcquisition · 2,45,05,435
Glenmark Pharmaceuticals LimitedDisposal · 2,45,05,435
Glenmark Pharmaceuticals LimitedDisposal · 6,73,89,944
Glenmark Pharmaceuticals LimitedPledge · 96,09,571
Substantial Acquisitions (SAST)

6 disclosure(s)

Offer For Sale11/07/2024 - 12/07/2024 · 96,09,571
Off Market12/03/2024 · 2,45,05,435
Off Market12/03/2024 · 2,45,05,435
Off Market06/03/2024 · 6,73,89,944
Off Market05/03/2024 - 06/03/2024 · 6,73,90,850
Encumbrance Shares21/09/2023 · —
Company Information
Incorporated2011
ChairmanHIREN KARSANBHAI PATEL
AuditorWalker Chandiok & Co LLP
Investor Email[email protected]
🌐 www.glenmarklifesciences.com ↗

📍 Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Alankit LimitedAlbert DavidAlcokraft Distillerie Ltd.Alembic LimitedAlgoquant Fintech LimitedAlicon Castalloy LimitedAlkali Metals Ltd.Alkem Laboratories Ltd.Alkyl Amines Chem. Ltd.Allcargo Logistics Ltd.Alldigi Tech LimitedAll E Technologies Ltd.All “A” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search